IPRATROPIUM ZENTIVA 0.50 mg/2 ml for adults, solution for inhalation by nebulizer in a single-dose container 10 single-dose containers of 2 ml
Active ingredients: Anhydrous ipratropium bromide, Ipratropium bromide
Commercialized according to BDPMDispensing in France: Prescription only
Solution for inhalation by nebulizer10 single-dose containers of 2 mlinhalée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- IPRATROPIUM ZENTIVA 0,50 mg/2 ml ADULTES, solution pour inhalation par nébuliseur en récipient unidose
- Pharmaceutical form
- solution pour inhalation par nébuliseur
- Route of administration
- inhalée
- Presentation description
- 10 récipient(s) unidose(s) polyéthylène basse densité (PEBD) de 2 ml
- Marketing authorisation holder
- ZENTIVA FRANCE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 2 May 2018
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Emergency use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62298607CIP73009079CIP133400930090794Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| BROMURE D'IPRATROPIUM MONOHYDRATÉsolution | — | SA |
| BROMURE D'IPRATROPIUM ANHYDREsolution | 0,500 mg · un récipient unidose de 2 ml | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.